Abstract
The risk of childhood acute lymphoblastic leukemia (ALL) differs across ethnic groups and there exist gaps in our understanding of the genetic risk of ALL as most studies took place in populations of predominantly European ancestries. In an effort to address these limitations, we performed a genetic meta-analysis of ALL in 76,317 participants across four ethnic groups, including 17,814 non-European individuals and 3,482 total cases. We replicated 15 out of 16 previously identified loci associated with ALL in our trans-ethnic analysis. We further identified five novel associations at genome-wide significance, including three novel loci and two secondary associations at previously known loci (17q12 and near CEBPE). The three putatively novel loci (rs9376090 near MYB/HBS1L, rs10998283 near TET1, and rs9415680 near JMJD1C/NRBF2) were previously shown to be associated with multiple blood cell traits and other hematopoietic cancers. Polygenic risk scores constructed from our trans-ethnic meta-analysis showed similar efficacy in independent Latino (LAT) and non-Latino white (NLW) ALL cohorts (AUC ∼ 0.67-0.68) and could partly explain the increased risk of ALL in LAT compared to NLW. Cross-population analysis also showed high but significantly less than 100% genetic correlation between LAT and NLW, suggesting potential differences in the underlying genetic architecture between ethnic groups. In summary, our findings enhance the understanding of genetic contribution to ALL risk across diverse populations and highlight the importance to include multiple ethnic groups in GWAS.
Key Points
We identified three novel loci on childhood acute lymphoblastic leukemia near genes previously associated with multiple blood cell traits
Polygenic risk scores using known and novel risk variants showed similar efficacy in Latino and non-Latino white Americans
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by research grants from the National Institutes of Health (R01CA155461, R01CA175737, R01ES009137, P42ES004705, P01ES018172, P42ES0470518 and R24ES028524) and the Environmental Protection Agency (RD83451101), United States. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health and the EPA. The collection of cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the National Cancer Institute's Surveillance, Epidemiology and End Results Program under contract HHSN261201000140C awarded to the Cancer Prevention Institute of California, contract HHSN261201000035C awarded to the University of Southern California, and contract HHSN261201000034C awarded to the Public Health Institute; and the Centers for Disease Control and Prevention's National Program of Cancer Registries, under agreement U58DP00386201 awarded to the California Department of Public Health. The biospecimens and/or data used in this study were obtained from the California Biobank Program, (SIS request #26), Section 6555(b), 17 CCR. The California Department of Public Health is not responsible for the results or conclusions drawn by the authors of this publication. We thank Hong Quach and Diana Quach for DNA isolation support. We thank Martin Kharrazi, Robin Cooley, and Steve Graham of the California Department of Public Health for advice and logistical support. We thank Eunice Wan, Simon Wong, and Pui Yan Kwok at the UCSF Institute of Human Genetics Core for genotyping support. This study makes use of data generated by the Wellcome Trust Case-Control Consortium. A full list of the investigators who contributed to the generation of the data is available from www.wtccc.org.uk. Funding for the project was provided by the Wellcome Trust under award 076113 and 085475. Genotype data for COG ALL cases are available for download from dbGaP (Study Accession: phs000638.v1.p1). Data came from a grant, the Resource for Genetic Epidemiology Research in Adult Health and Aging (RC2 AG033067; Schaefer and Risch, PIs) awarded to the Kaiser Permanente Research Program on Genes, Environment, and Health (RPGEH) and the UCSF Institute for Human Genetics. The RPGEH was supported by grants from the Robert Wood Johnson Foundation, the Wayne and Gladys Valley Foundation, the Ellison Medical Foundation, Kaiser Permanente Northern California, and the Kaiser Permanente National and Northern California Community Benefit Programs. The RPGEH and the Resource for Genetic Epidemiology Research in Adult Health and Aging are described here: https://divisionofresearch.kaiserpermanente.org/genetics/rpgeh/rpgehhome. For recruitment of subjects enrolled in the CCLS replication set, the authors gratefully acknowledge the clinical investigators at the following collaborating hospitals: University of California Davis Medical Center (Dr. Jonathan Ducore), University of California San Francisco (Drs. Mignon Loh and Katherine Matthay), Children's Hospital of Central California (Dr. Vonda Crouse), Lucile Packard Children's Hospital (Dr. Gary Dahl), Children's Hospital Oakland (Dr. James Feusner), Kaiser Permanente Roseville (formerly Sacramento) (Drs. Kent Jolly and Vincent Kiley), Kaiser Permanente Santa Clara (Drs. Carolyn Russo, Alan Wong, and Denah Taggart), Kaiser Permanente San Francisco (Dr. Kenneth Leung), and Kaiser Permanente Oakland (Drs. Daniel Kronish and Stacy Month). The authors additionally thank the families for their participation in the California Childhood Leukemia Study (formerly known as the Northern California Childhood Leukemia Study). Finally, the authors acknowledge the Center for Advanced Research Computing (CARC; https://carc.usc.edu) at the University of Southern California for providing computing resources that have contributed to the research results reported within this publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by California Department of Public Health Institutional Review Board.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Any uploading of genomic data and/or sharing of these biospecimens or individual data derived from these biospecimens has been determined to violate the statutory scheme of the California Health and Safety Code Sections 124980(j), 124991(b), (g), (h), and 103850 (a) and (d), which protect the confidential nature of biospecimens and individual data derived from biospecimens. This study was approved by Institutional Review Boards at the California Health and Human Services Agency, University of Southern California, Yale University, and the University of California San Francisco. The de-identified newborn dried blood spots for the CCRLP (California Biobank Program SIS request # 26) were obtained with a waiver of consent from the Committee for the Protection of Human Subjects of the State of California.
